Biotech · Private company
Ashvattha Therapeutics, Inc.
Track this companyFree. Adds Ashvattha Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials32 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- 18F-OP-801Phase 2 · Amyotrophic Lateral Sclerosis (ALS)ClinicalTrials.gov · fetched Nov 12, 2026
- D-4517.2Phase 2 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- OP-101Phase 2 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy VolunteersPHASE1_PHASE2 · RECRUITING · started Feb 2, 2023ClinicalTrials.gov NCT05395624 · fetched Nov 12, 2026
- Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DMEPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 31, 2022ClinicalTrials.gov NCT05387837 · fetched Nov 12, 2026
- A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) PatientsPHASE2 · TERMINATED · started Aug 11, 2020ClinicalTrials.gov NCT04458298 · fetched Nov 12, 2026